Montril (Montelukast)

Therapeutic Group : Bronchodilator & Antitussive

Presentation:

Montril-4 Tablet: Each oroflash tablet contains Montelukast Sodium USP 4.150 mg equivalent to Montelukast 4 mg.
Montril-5 Tablet: Each chewable tablet contains Montelukast Sodium USP 5.190 mg equivalent to Montelukast 5 mg.
Montril-10 Tablet: Each film coated tablet contains Montelukast Sodium USP 10.380 mg equivalent to Montelukast 10 mg.

Indications:

Montelukast is indicated for
– The prophylaxis and chronic treatment of asthma
– Relief of symptoms of Seasonal Allergic Rhinitis (SAR) and Perennial Allergic
Rhinitis (PAR)
– Acute prevention of Exercise-Induced Bronchoconstriction (EIB)

Dosage & Administration:

One Tablet should be taken in the evening as per the following instruction-
– Children 6 months to 5 years: 4 mg oroflash tablet.
– Children 6 to 14 years: 5 mg chewable tablet.
– 15 years & Older: 10 mg tablet.

Acute prevention of EIB: One tablet at least 2 hours before exercise for patients 6 years of age & older.

Contrainidications:

Montril is contraindicated to patients with hypersensitivity to any component of this product.

Warning & Precautions:

Montelukast should not be used in the reversal of bronchospasm in acute asthma attacks. Patients with known aspirin sensitivity should avoid aspirin or other NSAIDs, while taking Montelukast. In rare cases, patients on therapy with Montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition, which is often treated with systemic corticosteroid therapy. Physician should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal association between Montelukast and these underlying conditions has not been established.

Side effects:

Generally Montelukast is well-tolerated. Side effects include dizziness, headache, diarrhoea, restlessness, abdominal pain, cough, fever, asthenia, rash and upper respiratory tract infection.

Drug interaction:

Montelukast has been administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma.
Cytochrome P-450 inducers: Although Phenobarbital induces hepatic metabolism, no dosage adjustment for Montelukast is recommended. It is reasonable to employ appropriate clinical monitoring when potent cytochrome P-450 enzyme inducers, such as Phenobarbital or Rifampin are co-administered with Montelukast.

Use in special groups:

In pregnancy: Pregnancy category B drug. There are no adequate and well-controlled studies in pregnant women. Montelukast should be used during pregnancy only if clearly needed.
In lactation: It is not known if Montelukast is excreted in human milk. Caution should be excercised when Montelukast is given to nursing mother.

Packing:

Montril-4 Tablet: Each box contains 30’s tablets in blister pack.
Montril-5 Tablet: Each box contains 30’s tablets in blister pack.
Montril-10 Tablet: Each box contains 30’s tablets in blister pack.